Cell differentiation and iodine-131 uptake in poorly differentiated thyroid tumour in response to nevirapine

Lancet Oncology

Volumn 7, Issue 10, 2006, Pages 877-879

  Landriscina, Matteo ^a   Modoni, Sergio ^b   Fabiano, Annarita ^a   Fersini, Alberto ^a   Barone, Carlo ^c   Ambrosi, Antonio ^a   Cignarelli, Mauro ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; NEVIRAPINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

AGED; ARTICLE; BONE METASTASIS; CASE REPORT; CELL DIFFERENTIATION; CYTOREDUCTIVE SURGERY; DRUG MECHANISM; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR DIFFERENTIATION; WHOLE BODY SCINTISCANNING; WHOLE BODY TOMOGRAPHY;

AGED; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IODINE RADIOISOTOPES; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR CELLS, CULTURED;

EID: 33749263135     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70908-1     Document Type: Article

References (11)

1. Ren J., Nichols C., Bird L., et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 312 (2001) 795-805
2. Mangiacasale R., Pittoggi C., Sciamanna I., et al. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene 22 (2003) 2750-2761
3. Sciamanna I., Landriscina M., Pittoggi C., et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 24 (2005) 3923-3931
4. Landriscina M., Fabiano A., Altamura S., et al. Reverse transcriptase inhibitors downregulate cell proliferation in vitro and in vivo and restore TSH signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 90 (2005) 5663-5671
5. Spadafora C. Endogenous reverse transcriptase: a mediator of cell proliferation and differentiation. Cytogenet Genome Res 105 (2004) 346-350
6. Filetti S., Bidart J., Arturi F., et al. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141 (1999) 443-457
7. Ain K. Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 4 (2000) 615-629
8. Patel S., Johnson S., Belnap S., et al. Serious cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 35 (2004) 120-125
9. Schmutzler C., Winzer R., Meissner-Weigl J., and Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240 (1997) 832-838
10. Haugen B. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord 4 (2004) 175-180
11. Furuya F., Shimura H., Suzuki H., et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroblobulin. Endocrinology 145 (2004) 2865-2875